Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA102N Combined With TAS-102 vs Bevacizumab Combined With TAS-102 in mCRC
NCT06039202Phase 2Suspended
- Sponsor
- Holy Stone Healthcare Co., Ltd.
- Start
- Dec 2027
- Primary completion
- Oct 2030
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ca102n in colorectal cancer (CRC) (2 arms), sponsored by Holy Stone Healthcare Co., Ltd. Primary endpoints: Progression-Free Survival rate at 16 weeks and Adverse Events at 1 year. Planned start Dec 2027; status: suspended.
02
Drugs
ca102n
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06039202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039202.